FIELD: immunology.
SUBSTANCE: disclosed is a recovered human monoclonal antibody which binds to human MASP-2, as well as its antigen-binding fragment. Invention also discloses a nucleic acid coding molecule, an expression cassette, a cell and a method for producing an anti-MASP-2 antibody or an antigen-binding fragment thereof. Also described is a composition for treating a condition associated with MASP-2-dependent complement activation; use of an anti-MASP-2 antibody for preparing a drug and an industrial product for inhibiting MASP-2-dependent complement activation.
EFFECT: present invention can find further application in therapy of complement-mediated diseases.
15 cl, 24 dwg, 30 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| ANTI-IL31 ANTIBODIES FOR VETERINARY USE | 2018 |
|
RU2795485C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| BISPECIFIC ANTIBODIES SPECIFIC RELATIVELY TO COSTIMULATORY TNF-RECEPTOR | 2016 |
|
RU2761115C1 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
